Sarepta Therapeutics (SRPT) – Downgrades
-
Sarepta Therapeutics crushed after EMBARK misses primary endpoint, prompting 2 downgrades
-
Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to Perform, seeks "greater clarity on FDA feedback, timelines for potential full approval, full safety dataset"
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup